相关实验视频
Updated: Jan 10, 2026
06:09
An In Ovo Model for Testing Insulin-mimetic Compounds
Published on: April 23, 2018
11.1K
对伊朗2型糖尿病的6种非胰岛素药物的成本效益分析,使用UKPDS OM2的患者级模拟
Ali Darvishi1,2, Rajabali Daroudi3, Soroush Dehghan4
1Department of Health Policy and Management, School of Public Health and Safety, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Scientific reports
|November 25, 2025
概括
这项研究发现,皮奥格利塔是伊朗2型糖尿病 (T2DM) 的最具成本效益的治疗方法,在资源有限的环境中为个性化患者护理提供了与甲福林一起的有价值的选择.
科学领域:
- 卫生经济学 卫生经济学
- 药物经济学 药物经济学
- 内分泌学 在内分泌学.
背景情况:
- 2型糖尿病 (T2DM) 给全球健康带来重大负担,需要具有成本效益的管理策略.
- 优化治疗选择对于改善患者的治疗结果和医疗资源利用至关重要.
研究的目的:
- 评估六种非胰岛素药物 (NIA) 对伊朗T2DM治疗的成本效益.
- 根据每年质量调整寿命 (QALY) 的成本,比较皮奥格利塔,甲福尔,达帕格利弗洛辛,西塔格利普丁,恩帕格利弗洛辛和利拉格卢.
主要方法:
- 从医疗保健系统的角度来看,使用UKPDS结果模型2 (UKPDS-OM2) 的40年模拟.
- 分析了440名伊朗患者的数据,包括当地来源的成本和国际治疗效果的证据.
- 增量成本效益比率 (ICER) 被计算并与人均GDP值进行比较,不确定性通过引导代进行评估.
主要成果:
- 皮奥格利塔展示了最低的成本 (1376.20美元PPP) 和最高的QALY (8.47),主导了其他几种药物.
- 皮奥格利塔在各种子组中具有成本效益,而甲福林在特定的人口统计学中表现出偏好.
- 引导式分析证实了pioglitazone在52%的代中具有成本效益,在46%的代中使用了甲素.
结论:
- 皮奥格利塔是伊朗T2DM最具成本效益的NIA,而甲胺是可行的替代品.
- 建议采用个性化治疗策略,因为成本效益因患者的性别,年龄和糖尿病持续时间而异.
相关概念视频
01:12Analysis of Population Pharmacokinetic Data
659
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
659
01:26Pharmacokinetic Models: Comparison and Selection Criterion
314
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
314
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567
01:15Diabetes: Management and Pharmacotherapy
851
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
851
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
143
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
143
00:59Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
298
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
298